BECKMAN COULTER (SUBSIDIARY OF DANAHER CORP.)

History

Year	Detail
1935	Beckman Instruments Inc. founded by Dr. Arnold O. Beckman.
1952	The company became a publicly traded corporation.
1958	Wallace and Joseph Coulter founded Coulter Corporation as a private company.
1968	Beckman Instruments Inc. expanded its laboratory instrument focus.
1982	SmithKline Corporation acquired the company to form SmithKline Beckman Corporation.
1997	Beckman Instruments Inc later acquired Coulter Corp.
2009	The company acquired The Olympus Diagnostics Systems.
2012	Danaher purchased Beckman Coulter and divided the company into two operating companies, Diagnostics and Life Sciences.
2014	Beckman Coulter acquires Siemens Healthcare Diagnostics’ Clinical Microbiology Business.
2015	The company partnered with DiaSorin for Hepatitis and HIV Tests in China.
2016	Beckman Coulter and Ortho Clinical Diagnostics announce partnership to deliver Infectious Disease Testing Menu to high-volume labs.
2016	Beckman Coulter and Augusta University’s Medical Center signed a fifteen-year agreement collaborating on methods to improve patient outcomes.
2017	Introduced DxONE clinical information management tools.
2018	The company partnered with NTE-SENE and further announced the European launch of the DxM 6100 Autoplak Advanced System.
2018	The company launched the DxH 900 Hematology Analyzer.
2018	Beckman Coulter and U.S. ARKRAY Inc. announced a partnership and launched iQ Workcell in the United States.
2018	Beckman Coulter Diagnostics collaborated with Johns Hopkins Medicine in a healthcare innovation initiative.
2019	The company launched a new Procalcitonin Assay.
2020	The company launched DxH 690T in the U.S. market.
2020	Beckman Coulter expanded its partnership with BARDA to assess sepsis diagnostic and prediction algorithms with COVID-19 patients.
2020	Beckman Coulter launched the SARS-CoV-2 IgM antibody test.
2022	Beckman Coulter partnered with Smart4Diagnostics.
2022	Beckman Coulter partnered with Scopio Labs.
2023	Beckman Coulter partnered with Fujirebio.
2024	Beckman Coulter and Fujirebio expanded their partnership to develop Blood-based Neurodegenerative Disease Diagnostics.